Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis

 Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis

Shots:

  • The P-III RESET study involves assessing of Rivipansel (IV) vs PBO in 345 patients in a ratio (1:1) with SCD who were hospitalized for a VOC and required treatment with IV opioids aged ≥ 6yrs.
  • The P-III RESET (B5201002) study results demonstrated that it did not meet its 1EPs of time to readiness-for-discharge and 2EPs of time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids
  • Rivipansel is a glycomimetic therapy, acts as a pan-selectin antagonist and binds to E-, P- and L-selectin, being evaluated for VOC in patients with SCD. In 2011, Pfizer signs a WW license agreement with GlycoMimetics to develop & commercialize rivipansel

Click here to­ read full press release/ article | Ref: Pfizer | Image: Stat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post